This trial is studying the side effects and best dose of daratumumab, ixazomib, and dexamethasone in treating patients with amyloid light chain amyloidosis.
2 Primary · 6 Secondary · Reporting Duration: Up to 24 months
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: Dexamethasone · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: